Afimoxifene

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Afimoxifene
Afimoxifene2DACS.svg
Clinical data
Routes of
administration
Topical (gel)
Identifiers
Synonyms 4-Hydroxytamoxifen
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.155.464
Chemical and physical data
Formula C26H29NO2
Molar mass 387.5139 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Afimoxifene,[1] also known as 4-hydroxytamoxifen (4-OHT, 4-HT, OHTAM, others), is a selective estrogen receptor modulator (SERM) of the triphenylethylene group and the major active metabolite of tamoxifen.[2] The drug is under development by Ascend Therapeutics under the tentative trademark TamoGel as a topical gel for the treatment of cyclical mastalgia (breast pain).[3] It has completed a phase II clinical trial for this indication,[4] but further studies are required before afimoxifene can be approved for this indication and marketed.[3]

A study in France on 55 women showed that rubbing afimoxifene on the skin was as effective as oral tamoxifen at slowing breast cancer growth. A United States trial will compare 6 weeks use before breast cancer surgery. Skin application can reduce systemic levels by a factor of nine and this is expected to reduce the unpleasant side-effects of tamoxifen.[5]

In addition to its antiestrogenic and estrogenic activity, afimoxifene has been found to act as an antagonist of the estrogen-related receptors (ERRs) ERRβ and ERRγ.[6][7]

See also[edit]

References[edit]

  1. ^ "Statement on a nonproprietary name adopted by the USAN council: Afimoxifene" (PDF). American Medical Association. Retrieved 2008-03-26. 
  2. ^ Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004). "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6". J Pharmacol Exp Ther. 310 (3): 1062–1075. doi:10.1124/jpet.104.065607. PMID 15159443. 
  3. ^ a b Ismail Jatoi; Achim Rody (16 November 2016). Management of Breast Diseases. Springer. pp. 77–. ISBN 978-3-319-46356-8. 
  4. ^ Mansel R, Goyal A, Nestour EL, Masini-Etévé V, O'Connell K (2007). "A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women". Breast Cancer Res. Treat. 106 (3): 389–397. doi:10.1007/s10549-007-9507-x. PMID 17351746. 
  5. ^ Hagan, Pat (6 Aug 2011). "Breast cancer gel shrinks tumours". Daily Mail. London. 
  6. ^ Alice C. Levine (3 October 2011). Hormones and Cancer: Breast and Prostate, An Issue of Endocrinology and Metabolism Clinics of North America,. Elsevier Health Sciences. pp. 271–. ISBN 1-4557-1239-6. 
  7. ^ Sushil K. Khetan (23 May 2014). Endocrine Disruptors in the Environment. Wiley. pp. 104–. ISBN 978-1-118-89115-5. 

External links[edit]